Intranasal corticosteroid technique and decongestant overuse

01Purpose and principlesWhat the treatment does and how it fits into care.

Nasal treatment often fails because the medicine is misidentified, used intermittently or deposited on the septum or in the throat. A short observed demonstration can uncover these problems more effectively than asking whether the patient knows how to use a spray. Technique teaching should use the actual bottle: suspension products may require shaking, and priming and cleaning instructions vary. The aim is useful delivery to the nasal mucosa with minimal irritation and swallowing.

Intranasal corticosteroids suppress inflammation and can be used as regular maintenance for an appropriate diagnosis. Xylometazoline and oxymetazoline rapidly constrict mucosal vessels and are short-term decongestants. Prolonged use can cause worsening congestion as the effect wears off, declining effectiveness and, with continued exposure, rhinitis medicamentosa. The current MHRA warning reduces the maximum continuous duration to five days. An older pack or webpage stating seven days should not override the updated safety advice.

Key points

Check the active ingredient because a corticosteroid and a vasoconstrictor have different purposes, onset and duration limits.
Corticosteroid sprays work through regular anti-inflammatory treatment and do not need to create an immediate unblocking sensation to be effective.
Clear the nose gently, follow device-specific priming instructions and keep the head slightly forward during administration.
Aim the nozzle away from the septum and use gentle inspiration rather than forcefully drawing medicine into the throat.
Review local bleeding, other steroid routes and strong CYP3A inhibitors before escalating a nasal corticosteroid.
MHRA advice from April 2026 limits xylometazoline and oxymetazoline nasal sprays or drops to five consecutive days.
Avoid combining these nasal decongestants with other oral or nasal sympathomimetic decongestants.
For established overuse, explain rebound congestion and agree gradual withdrawal, appropriate alternatives and follow-up.

02Indications, selection and cautionsWho may benefit, who needs urgent treatment and important alternatives.

Identify the actual preparation

Ask the patient to bring the bottle or show a photograph of the label. Record active ingredients, strength, sprays per nostril, daily frequency and total duration, including cold remedies bought separately from pharmacies or online.

Observe delivery

Look for a backward-tilted head, nozzle aimed towards the septum, a forceful sniff or medicine running immediately into the throat. Ask about bitter taste, irritation and bleeding, which may reveal a delivery problem before a dose is changed.

Recognise decongestant dependence

A patient may report shorter relief, increasing frequency and worsening blockage between doses after weeks of vasoconstrictor use. Explain that these symptoms can be caused by the treatment cycle rather than proving that the original infection remains active.

Assess safety modifiers

Review recent surgery or trauma, local infection, septal damage and pregnancy. Ask about inhaled, oral, topical and injected steroids and interacting medicines, particularly ritonavir or cobicistat-containing treatment.

Red flags requiring action

New visual disturbance during corticosteroid treatment requires assessment; sudden visual loss or significant eye pain needs urgent ophthalmic review.
Persistent unilateral bleeding or obstruction despite a spray adjustment requires direct nasal examination and appropriate ENT referral.

03Assessment before treatmentTests and checks that guide safe selection.

Investigation order

Read from the initial assessment onwards. Tests may run in parallel in urgent care; first-line, preferred, confirmatory, definitive and gold-standard labels appear only when the chapter explicitly states them.

01
Observed technique and medicine reconciliationFirst step
Why
Identify remediable delivery errors and duplicate ingredients before escalation.
Interpretation and limitations
A demonstration often explains apparent treatment failure. Compare what the patient actually uses with the prescribed product, especially when brand changes or multi-ingredient cold remedies have caused confusion.
02
Focused nasal examination
Why
Assess bleeding, irritation, structural disease and persistent obstruction.
Interpretation and limitations
Inspect the septum and visible mucosa when symptoms persist or bleeding occurs. Local trauma may improve with technique correction, but a suspicious lesion or unexplained unilateral finding needs a separate assessment.
03
Targeted review of systemic corticosteroid risk
Why
Identify patients in whom cumulative exposure or interactions matter.
Interpretation and limitations
Routine endocrine testing is unnecessary for every standard nasal prescription. High doses, prolonged exposure, symptoms of adrenal dysfunction or potent interactions justify an individual clinical assessment and specialist advice where indicated.
04
Assessment of the underlying nasal disorder
Why
Choose a sustainable alternative when a decongestant is withdrawn.
Interpretation and limitations
Allergy, non-allergic rhinitis, polyps and fixed obstruction require different plans. Rebound congestion can coexist with one of these conditions, so withdrawal alone may not address the original reason for use.

04Treatment approachPreparation, options, escalation and aftercare.

01Technique demonstrationDeliver the medicine to nasal mucosaFirst stepA nasal corticosteroid is being started or response has been disappointing.

1Check the device leaflet for shaking and priming, then gently clear the nose before administration.
2Hold the bottle upright with the head slightly forwards and place the nozzle just inside the nostril.
3Direct the nozzle towards the outer nasal wall, away from the septum; using the opposite hand can help achieve this angle.
4Breathe in gently as the spray is released and avoid a forceful sniff that pulls the dose into the throat.
5Wipe and recap the nozzle as instructed, then ask the patient to demonstrate the technique back.

02Maintenance reviewUse the lowest effective regular regimenAn appropriate inflammatory diagnosis requires ongoing intranasal corticosteroid treatment.

1Explain that regular use and an adequate treatment period are needed before judging full benefit.
2Use the product- and indication-specific dose, reducing to effective maintenance when control permits.
3Review local adverse effects and interaction risks before increasing dose or combining preparations.
4Agree when to reassess symptoms and when a change in diagnosis or specialist referral is needed.

03Decongestant overuseBreak the cycle with supported withdrawalXylometazoline or oxymetazoline has been used beyond the recommended short course.

1Explain rebound congestion, reduced responsiveness and the reason for the current five-day maximum for new courses.
2Agree an individual gradual withdrawal plan; an abrupt stop can worsen symptoms and make the plan harder to sustain.
3Treat the underlying disorder with appropriate alternatives, such as saline or an indicated intranasal corticosteroid.
4Do not substitute another nasal vasoconstrictor or add an oral sympathomimetic as an automatic workaround.
5Arrange review of recovery, persistent mucosal changes and any need for ENT assessment.

05Regimens, contraindications and interactionsTreatment details and the circumstances that modify them.

A product-specific example combining regular anti-inflammatory dosing with device preparation.

Nasonex 50 micrograms per spray for adult allergic rhinitis

Use two actuations into each nostril once daily, providing 200 micrograms daily; reduce to one actuation per nostril daily when controlled. For this device, prime ten times before first use and reprime twice after fourteen days or more without use; shake before each administration.

Discard according to the labelled actuation count or within two months after opening. Avoid untreated local nasal infection and unhealed nasal trauma or surgery. Check persistent epistaxis, septal perforation, visual symptoms and corticosteroid interactions; the instructions differ for other products and indications. Nasonex is not recommended in patients with a nasal septal perforation.

A combination option when allergic symptoms are insufficiently controlled by either component alone.

Dymista azelastine and fluticasone propionate combination spray

For adults and adolescents aged twelve or over, give one actuation into each nostril morning and evening during the relevant allergen exposure period. Shake gently for about five seconds; prime six times initially and reprime once after more than seven days without use.

Keep the head downward and avoid eye contact. Review fatigue, dizziness, alcohol or sedative use, severe hepatic disease and potent CYP3A inhibitors. Pregnancy or lactation use requires justified benefit-risk assessment. Do not use below the product's recommended age or duplicate fluticasone through another nasal preparation without review.

A selected short-term vasoconstrictor option for congestion, distinct from maintenance anti-inflammatory treatment.

Otrivine Blocked Nose Relief 0.1% xylometazoline adult spray

Use one application into each nostril up to three times daily, never exceeding three applications per nostril in a day. Limit a new course to five consecutive days under the April 2026 MHRA update, which supersedes the older seven-day duration still present in this SmPC.

Do not use with hypersensitivity, below twelve years, with narrow-angle glaucoma, atrophic rhinitis, phaeochromocytoma, prostatic hypertrophy, relevant dura-exposing surgery or current MAOI use or use within the previous two weeks. Concurrent use with other oral or nasal sympathomimetic decongestants is contraindicated under the MHRA update. Assess hypertension, cardiovascular disease, long QT, hyperthyroidism, diabetes and tricyclic or tetracyclic antidepressants. Avoid in pregnancy; breastfeeding use needs medical advice.

06Complications, monitoring and follow-upAdverse effects, response and longer-term review.

Review whether the patient can administer the dose comfortably and consistently, especially after a change of device or brand.
Ask about bleeding, soreness, crusting, unpleasant taste and persistent symptoms; correct delivery before escalating treatment where appropriate.
Monitor children receiving prolonged corticosteroid treatment according to the product guidance, including growth and the total steroid burden.
During decongestant withdrawal, agree a realistic review interval and explain that recovery may take time; the MHRA notes that early recognised cases typically recover within three months.
Persistent severe obstruction or visible mucosal changes after withdrawal needs reassessment of both medication injury and the underlying nasal condition.
Encourage reporting of suspected decongestant adverse reactions through the MHRA Yellow Card scheme, with product, duration and concurrent treatment details.

07Special situationsVariants, exceptions and circumstances that change the usual approach.

Five days means five consecutive days

The April 2026 MHRA update replaces the older seven-day maximum for xylometazoline and oxymetazoline in adults and older children. Product information is transitioning, so counsel explicitly rather than relying on an old duration printed on a familiar pack.

Long-term does not mean risk free

Local corticosteroids usually have less systemic exposure than oral treatment, but high doses and potent metabolic inhibitors can increase adverse effects. Fluticasone with ritonavir or cobicistat needs particular attention; avoid the combination unless benefit justifies risk and monitoring is arranged.

Withdrawal is an active treatment plan

A patient who has become reliant on rapid relief may struggle when congestion increases during reduction. Agree practical steps, alternatives and follow-up rather than giving a brief instruction to stop and leaving the original obstruction untreated.

Different preparations need different instructions

Sprays, drops and specialist steroid irrigations are not interchangeable techniques. Use the instructions for the prescribed formulation; a spray demonstration should not be applied automatically to drops or a postoperative irrigation prescription.

08Common pitfallsFrequent interpretation and management errors.

01
Describing every nasal spray as a decongestant and thereby confusing maintenance treatment with a short-course vasoconstrictor.
02
Aiming towards the septum or tilting the head backwards and then increasing the dose because medicine tastes unpleasant in the throat.
03
Repeating an old seven-day xylometazoline instruction after the MHRA changed the maximum duration to five days.
04
Adding oral pseudoephedrine to nasal oxymetazoline without recognising duplicate sympathomimetic treatment.
05
Assuming nasal fluticasone cannot interact with ritonavir because it is applied locally.
06
Stopping a long-established decongestant without discussing rebound symptoms, a gradual plan and treatment of the original nasal disorder.